NCT05955521Active, not recruiting
Exosome as the Prognostic and Predictive Biomarker in EBC Patients
Development of a Prognostic and Predictive Biomarker for Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy Using Exosome
Source: ClinicalTrials.gov · Last updated 21 Jul 2023
Brief summary (registry, in English)
This study is the experimental study for serial ctDNA and exosome evaluation in EBC patients
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 200 (actual)
- First submitted
- 13 Jul 2023
- Start date
- 1 May 2021
- Primary completion date
- 1 Jul 2023
- Lead sponsor
- Samsung Medical Center
- NCT number
- NCT05955521
What you commit to
- Study type: Interventional
- Participants enrolled: 200
- From 1 May 2021 to the primary completion date, 1 Jul 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Stage IV breast cancer
- Hormone receptor positive breast cancer
Who the study is looking for
- Early breast cancer
- Planned neoadjuvant chemotherapy
- Triple negative breast cancer or HER2-positive breast cancer
Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ji-Yeon Kim Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.